Value through Innovation27 July 2016

Clinical Study Results

  • BI 836826 - Lymphoma, Large B-Cell, Diffuse
    Clinical Study Number 1270.11
    Study Indication Lymphoma, Large B-Cell, Diffuse
    Product BI 836826
    Generic Name BI 836826
    Lab Code BI 836826
    Clinical Phase I/II
    Study Title

    An Open Label Multicenter Phase Ib/II Trial to Determine the Dose of BI 836826 in Combination With Gemcitabine and Oxaliplatin (GemOx) and the Efficacy of BI 836826-GemOx Versus Rituximab (R)- GemOx (R-GemOx) in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma (DLBCL) Who Are Not Eligible for, or Have Relapsed/Progressed After Autologous/Allogeneic Stem Cell Transplant

    Study Document Trial synopsis 1270.11 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.